Previous Article | Next Article ![]()
Journal of Virology, July 2000, p. 6494-6500, Vol. 74, No. 14
ABL-Basic Research Program, NCI-Frederick
Cancer Research and Development Center, Frederick, Maryland
21702-1201
Received 14 February 2000/Accepted 26 April 2000
We compared the fidelity of wild-type human immunodeficiency virus
type-1 (HIV-1) reverse transcriptase (RT) and two RT mutants, Y115F and
Y115V. Although neither mutation had a large effect on the overall
fidelity of the enzyme, both mutations altered the spectrum of
mutations and the precise nature of the mutational hot spots. The
effects of Y115V were greater than those of Y115F. When we compared the
behavior of the wild-type enzyme with published data, we found that, in
contrast to what has been published, misalignment/slippage could
account for only a small fraction of the mutations we observed. We also
found that a preponderance of the mutations (both transitions and
transversions) resulted in the insertion of an A. Because we were
measuring DNA-dependent DNA synthesis (plus-strand synthesis), this
bias could contribute to the A-rich nature of the HIV-1 genome.
The replication of the human
immunodeficiency virus type 1 (HIV-1) genome is error prone, giving
rise to genetic variation. This genetic variation is important both for
the ability of the virus to evade the host's immune system and for the
emergence of drug-resistant variants. There are three steps in the
viral life cycle in which mutations can occur: (i) when an infected cell divides, the proviral form of the viral genome is copied by the
host's DNA replication machinery; (ii) when the virus is produced by
an infected cell, the RNA genome of the virus is generated by the
host's DNA-dependent RNA polymerase; and (iii) when the virus infects
a cell, viral reverse transcriptase (RT) converts the RNA genome of the
virus into DNA. The overall error rate for this process is relatively
high (about 10 One way to approach this problem is to study the fidelity of RT in
vitro. Both biochemical and genetic approaches have been used to
measure RT fidelity. Biochemical approaches involve mispair extension
assays or assays measuring misincorporation on either a homopolymeric
or a defined heteropolymeric template (18, 19, 26). Genetic
fidelity approaches involve copying a DNA or RNA segment encoding an
activity that can be conveniently assayed in vivo (usually, but not
always, the segment encoding the Genetic assays have several advantages. They are not appreciably
affected by the purity of individual deoxynucleoside triphosphate (dNTP) stocks which can be an important issue in certain biochemical fidelity assays. Furthermore, unlike mispair extension assays, genetic
fidelity assays use normal polymerase substrates in which the template
primer is fully base paired and all four dNTPs are present at normal
concentrations. These advantages do not mean, however, that genetic
fidelity assays are without problems. The E. coli host can
make unwanted contributions to a genetic fidelity assay. Fortunately,
the error rate for the host DNA replication machinery is low enough
relative to the error rate of RT that the E. coli machinery
does not significantly increase the overall mutation frequency for RT.
If both the strand that has been copied in vitro and a complementary
strand are introduced into E. coli, mutations generated by
RT in vitro can be corrected against the complementary strand by the
mismatch repair machinery of the bacterial host. If the two strands are
corrected against each other with equal efficiency, the error rate is
underestimated by a factor of 2. This outcome is not optimal but has a
relatively modest effect on the measured error rate. However, if the
segment generated in vitro by the DNA polymerase whose fidelity is
being tested is introduced into a plasmid or viral genome in a way that
leaves a nick on the strand synthesized in vitro, the presence of the nick can bias the mismatch repair. The E. coli repair
machinery can selectively degrade the nicked strand and thus can
correct the strand made in vitro against the intact strand, which can affect the error rate to a much greater extent.
After looking carefully at the available genetic assays for fidelity,
we made modifications to the published procedures to try to minimize
the problems associated with E. coli mismatch repair. The
DNA segment that is used as a template for in vitro DNA synthesis is
obtained from a Dut We used this assay to measure the fidelity of wild-type HIV-1 RT and
HIV-1 RTs with mutations at position 115, which is part of the
dNTP-binding site (9, 10, 13). The two mutants studied, Y115F and Y115V, have overall error rates similar to the error rate for
the wild-type enzyme. However, the spectrum of mutations made by the
mutant RTs differs from the spectrum of mutations generated by the
wild-type enzyme.
Plasmids.
Litmus 29 was obtained from New England BioLabs.
The plasmid contains an M13 origin of replication and a restriction
enzyme recognition site polylinker, including a recognition site for BamHI, 5' of the coding region for the LacZ Formation of single-strand uracil-containing DNA.
The
construct Litmus 29 (Not) was introduced into the Dut
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Effects of Amino Acid Substitutions at Position 115 on the Fidelity of Human Immunodeficiency Virus Type 1 Reverse
Transcriptase
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
4 errors/bp in a single replication cycle);
however, the relative contributions of the various steps and enzymes to
this overall error rate are not known (see reference
23 for a review). It is likely that the host's
DNA-dependent DNA polymerase, which has a high fidelity and an
associated proofreading function, does not make a major contribution to
the error rate in situations in which the virus is actively
replicating. However, the relative roles played by RT and the host's
DNA-dependent RNA polymerase in the generation of mutations are unclear.
-complementing peptide of
Escherichia coli
-galactosidase). In such genetic fidelity assays, the segment is copied in vitro and incorporated into a
plasmid or the genome of a bacteriophage (or phagemid), usually an M13
derivative, and mutations are scored after transformation of a suitable
E. coli host (see reference 6 for review).
Ung
strain, so that the
template contains some deoxyuracil. In our modified assay, after the
DNA segment is copied in vitro, it is cleaved with restriction enzymes,
gel purified, and ligated to an appropriately cleaved plasmid. This
ligated DNA is reintroduced into a strain of E. coli that
will degrade uracil-containing DNA (U-DNA), ensuring that the strand
created in vitro by RT is preserved.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-complementing
fragment. Litmus 29 was linearized with HpaI, ligated to
NotI linkers (New England BioLabs), and recircularized to
make Litmus 29 (Not). The new NotI recognition sequence is
located 3' of the lacZ
-coding region.
Ung
male E. coli strain CJ236 (New England
BioLabs). This bacterial strain will introduce deoxyuracil residues
into the plasmid DNA during replication. To generate single-stranded
U-DNA Litmus 29 (Not), the helper phage M13K07 (New England BioLabs)
was used according to the protocol suggested by New England BioLabs. In brief, 50 ml of Luria-Bertani medium supplemented with uridine (0.25 µg/ml) was inoculated with a colony of Litmus 29 (Not) in CJ236. The
culture was incubated at 37°C with agitation until the solution was
slightly turbid. The helper phage M13K07 was added to a final
concentration of 108 PFU/ml. The culture was incubated at
37°C with agitation for an additional 60 min. Kanamycin was added to
a final concentration of 70 µg/ml, and the culture was incubated
overnight at 37°C.
20°C.
Fidelity assay.
The fidelity primer (5' CCC ATG GTG AAG CTT
GGA TCC ACG ATA TCC TGC AGG 3'; Life Technologies, Inc., Rockville,
Md.) matches the sequence surrounding the BamHI recognition
site in the Litmus 29 polylinker. For each fidelity assay, 2.5 µl
from a 10.0-A260/ml stock of fidelity primer was
annealed to 1.0 µg of single-stranded U-DNA (described above) by
heating and slow cooling. Each sample was adjusted to consist of 25 mM
Tris-Cl (pH 8.0), 75 mM KCl, 8.0 mM MgCl2, 2 mM
dithiothreitol, 100 µg of bovine serum albumin per ml, 10 mM CHAPS
{3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate}, and
20 µM each dATP, dCTP, dGTP, and dTTP. One microgram of either wild-type HIV-1 RT or the Y115F mutant was added, and the samples were
incubated for 15, 20, or 30 min at 37°C. For Y115V, which is less
processive than wild-type RT (18), longer incubation times
(20, 30, or 45 min) were used. The reactions were stopped by the
addition of 1 volume of phenol-chloroform, followed by isopropanol
precipitation and a 70% ethanol wash. The extended template primers
were digested with BamHI and NotI, and the
resulting fragments were fractionated on a 2% SeaPlaque (FMC)
low-melting-point agarose gel. If the wild-type or variant RT copied
the lacZ
portion of the template past the NotI
recognition sequence, a band approximately 300 bp in size was visible
in the gel. Primers that were not extended past the NotI
site were annealed to phage DNA that was linearized with
BamHI which migrated near the top of the gel. The
BamHI/NotI fragment encoding LacZ
was isolated
from the gel and purified.
-coding region. Attempting to remove this fragment and replace
it with the BamHI/NotI fragment generated by
HIV-1 RT could lead to a high-background problem that would not be
easily detected. Therefore, Litmus 29 (Not) was linearized with
BamHI/NotI and ligated to a 1.7-kb fragment
containing the coding region from HIV-1 RT and small flanking sequences
to yield the construct B/N RT (His). The LacZ
-coding region was
completely removed from this vector. B/N RT (His) was linearized with
BamHI and NotI, and the vector band was isolated
from a 2% SeaPlaque low-melting-point agarose gel. This DNA segment
was then ligated to the BamHI/NotI lacZ
fragments described above. The ligation mixture was
transformed into E. coli DH5
(Life Technologies, Inc.)
and plated on NZY (10.0 g of NZ amine, 5.0 g of NaCl, 5.0 g of yeast
extract, and 2.0 g of MgSO4 per liter)-ampicillin plates
supplemented with 5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside (X-Gal;
Life Technologies). The dark blue, light blue, and white colonies were then counted.
DNA was isolated from the light blue and white colonies and tested by
digestion with BamHI and NotI. Contaminating B/N
RT (His) colonies were easily distinguished since plasmid DNA isolated from these colonies contained a 1.7-kb insert that was much larger than
the approximately 300-bp lacZ
insert. The remaining
clones were then sequenced to determine the nature of the mutation.
| |
RESULTS |
|---|
|
|
|---|
Fidelity assay.
The fidelity assay that we have used involves
the copying of a DNA segment that encodes the
-complementing peptide
of E. coli
-galactosidase. As described in Materials and
Methods, single-stranded template DNA from Litmus 29 (Not) was isolated
from a Dut
Ung
E. coli strain.
In such strains, deoxyuracil is incorporated into DNA. The template
U-DNA was hybridized to a primer, which was extended in vitro by either
the wild-type or mutant HIV-1 RT so that the DNA segment encoding the
-complementing peptide was copied. The resulting double-stranded DNA
was digested, and the fragment containing the LacZ
coding region was
ligated to a plasmid and introduced into a Dut+
Ung+ E. coli strain, which ensures that the
template DNA strand is preferentially degraded and that the DNA strand
synthesized in vitro by HIV-1 RT is preferentially retained and copied,
giving rise to the plasmids subsequently isolated from individual
colonies. The transformed E. coli was grown on plates
containing an indicator for
-galactosidase activity (X-Gal).
Colonies that were either white or light blue were counted and grown
up, and the plasmids were recovered. Segments encoding the LacZ
peptide were sequenced (Materials and Methods). Since a percentage of
mutations will be silent, this method necessarily underestimates the
actual error rate. However, when RT copies the viral genome, a
percentage of the mutations will also be silent. In addition, copying
the lacZ
-complementing DNA has been used by others to
examine both the frequency of errors made by HIV-1 RT and the precise
nature of the mutations.
RNA transcript from Litmus 29 (Not) encodes a
fusion protein. The LacZ
peptide is the C-terminal part of the
fusion protein; the N terminus, which makes no functional contribution to LacZ
activity, is derived from the polylinker. A small part of
the N-terminal region of this fusion protein is encoded with the
NotI/BamHI fragment generated in vitro by RT.
Because this region does not encode a functional part of LacZ
, only
mutations that create termination codons or frameshift mutations will
be detected, potentially skewing the results. Therefore, we scored only
mutations within the 174-bp region from the glycine codon GGA, which is
the junction point between lacZ
and the polylinker and
the first termination codon at the end of lacZ
.
Wild-type HIV-1 RT.
To facilitate a comparison of our results
and those obtained by others, we first analyzed wild-type HIV-1 RT
(Fig. 1 and
2; Tables 1
and 2). The overall measured error rate
of 1.6 × 10
4 mutations/bp is within the range
others have reported (3-8, 11, 21; see reference
23 for a review). Of 222 total mutations analyzed,
49 (22%) were transitions, 140 (63%) were transversions, and 33 (15%) were frameshifts (Table 2). Among the transitions and
transversions, the majority of the mutations involved changes in which
the base introduced into the sequence was an A (Table 3; Fig. 1). Of the missense mutations
generated by wild-type HIV-1 RT, 88% (166 of 189) involved the
replacement of another base with an A (Table 3). If this reflects what
happens during plus-strand DNA synthesis in vivo (the step in which RT
copies a DNA strand), it might help to account for the fact that the HIV-1 genome is A rich (see Discussion).
|
|
|
|
|
Fidelity of the Y115F mutant.
Position 115 is part of the
dNTP-binding pocket. In RTs from lentiviruses, the amino acid at this
position is Y; in most other retroviral RTs, the amino acid at the
equivalent position is F. In the case of HIV-1, the Y115F mutation is
associated with low levels of resistance to the nucleotide analog
1592U89 (24). The change from Y to F at position 115 causes
the loss of a hydroxyl group; however, the phenyl ring is preserved.
The overall error rate for Y115F is 1.0 × 10
4/bp,
which is slightly lower than the overall error rate of the wild-type
enzyme (1.6 × 10
4/bp). We have compared the types
of errors made by the wild-type and mutant enzymes in two ways: by
calculating, for each class of mutations, the percentage of total
errors and the absolute frequencies they represent (Table 2). Y115F
makes a higher percentage of transitions (48%) and a lower percentage
of transitions (48%) and a lower percentage of transversions and
frameshifts (43 and 8%) than wild-type RT (43 and 8%). However, it
may be more useful to compare absolute error rate for the two enzymes.
This makes it clear that Y115F makes slightly more transitions than
wild-type RT (4.8 × 10
5 versus 3.5 × 10
5); however, the real difference is in the numbers of
transitions and frameshifts. Again, for the missense mutations,
substitutions of A predominates (Table 3). This is a slightly lower
percentage of A substitutions than for the wild type (73% versus
88%). Direct comparison of mutations obtained with Y115F to those made
by wild-type RT revealed that there were hot spots for mutations with
the wild-type enzyme (for example, positions 61, 87, 90, 108, 129, 131, 133, and 150) that are not hot spots for Y115F (Fig. 1). Two of these, 90 and 108, are positions where the mutations could be explained by a
misalignment/slippage mechanism, suggesting that Y115F may be less
prone to this type of error than the wild-type enzyme. Consistent with
such an interpretation, the absolute rate of frameshift errors is
reduced about threefold (from 2.4 × 10
5 to 8 × 10
6).
Fidelity of the Y115V mutant.
As might be expected, the
pattern of mutations generated by the Y115V mutant differs from that of
the wild-type enzyme to a greater degree than does the pattern
generated by Y115F. The overall mutation rate for Y115V is lower
(4.7 × 10
5 [Table 1]), and transitions are the
most common type of mutation (19/25 [76%] [Table 2]). The
remaining mutations are all transversions (6/25 [24%] [Table 3]);
no frameshifts were seen in the sample we analyzed. Because the overall
fidelity of Y115V is higher than that of wild-type HIV-1 RT, it is also
useful to compare the absolute error frequencies. The rate of
transitions is the same as for wild-type RT (3.5 × 10
5); however, the rate of transversions is almost an
order of magnitude lower (1.0 × 10
4 for wild-type
RT, 1.1 × 10
5 for Y115V). A substitution is still
the most common type of missense mutation (15/25 [76%]); however,
the pattern of mutational hot spots is different from that seen with
either Y115F or wild-type HIV-1 RT (Fig. 1). At one of the sites that
is a hot spot for Y115V (position 147), some, but not all, of the
changes could be accounted for by a misalignment/slippage mechanism.
| |
DISCUSSION |
|---|
|
|
|---|
We chose to use the DNA segment encoding the
-complementing
fragment of E. coli
-galactosidase because it is a
convenient target and because it has been used by others, making it
possible to directly compare our results with those already published. We modified the system to avoid bias in strand repair in E. coli that could preferentially cause degradation of the DNA strand synthesized by HIV-1 RT. The overall mutation rate that we measured for
wild-type HIV-1 RT (1.6 × 10
4) is not dramatically
different from what has been reported in the literature (reviewed in
reference 23). However, when the mutations are
examined directly, it is clear that our data differ substantially from
what has been published.
Although we found hot spots in the lacZ
sequence where
mutations arise frequently, these hot spots are not the same as those reported previously. The spectrum of mutations that we observed is also
different. Perhaps this difference is not surprising
two laboratories
that both used the same assay reported relatively different patterns of
mutations (4, 11). We found more transversions and fewer
frameshifts than have been reported previously. It has been suggested
that a large fraction of the errors made by wild-type HIV-1 RT in vitro
(both missense and frameshift) involve misalignment/slippage followed
by DNA synthesis (3, 4, 16, 17). Although we found some
missense mutations that can be explained by such a mechanism, they
represent a relatively small percentage of the total. In contrast, the
majority of the frameshift mutations can be explained by a
misalignment/slippage mechanism; however, we found that wild-type HIV-1
RT makes a lower percentage of frameshift mutations than has been
reported earlier (3, 4), and the two mutant enzymes that we
have tested produce fewer frameshift mutations than does wild-type
HIV-1 RT.
We do not have a simple explanation for these differences. We made changes in the assay that were intended to prevent the E. coli mismatch machinery from correcting errors introduced by HIV-1 RT. However, the differences between our results and those reported previously are not so much in the frequency of mutation as in the exact nature of the mutations obtained.
In addition to the changes that we introduced to make the assay more
reliable, we used a heterodimeric form of HIV-1 RT. Although most of
the original work with genetic assays was done with homodimeric HIV-1
RT (1, 17, 22), it was reported that experiments done with
heterodimeric RT obtained from virions gave results similar to those
obtained with recombinant HIV-1 RT (3, 8, 22). This finding
suggests that the explanation of the differences in the results lies in
the differences in the assays. We considered the possibility that
uracil in the template DNA strand would be mutagenic; however, this
should give rise to an increase in error rate and, more specifically,
to G
A transitions. We did find some G
A transitions, but these
were not the most common mutations. Comparison of the data obtained
with the two RT mutants to results obtained with wild-type HIV-1 RT
showed that there are no hot spots in common at which the predominant
mutation is G
A.
The most striking aspect of our results is the high percentage of mutations in which an A is substituted for another base in both transitions and transversions. The template that we have used is not particularly T rich; however, the product strand would become A rich if it were repeatedly copied using a polymerase that preferentially inserted A's for other bases. As mentioned in Results, the genome of HIV-1 is A rich. If, during reverse transcription in vivo, RT in the DNA-dependent DNA synthesis mode (copying minus-strand DNA, synthesizing plus-strand DNA) preferentially substitutes A's for other bases, this could introduce A's into the HIV-1 genome.
During viral replication in vivo, any errors made during plus-strand
synthesis could be corrected by the DNA repair machinery of the host.
However, there is no reason to expect that the host machinery could
distinguish the viral strands; it seems reasonable to expect that there
is an equal probability that the minus strand would be corrected based
on the plus-strand sequence as for a correction in the opposite
direction. This suggests, even if there is extensive mismatch
correction, that the host DNA repair machinery would be expected to
reduce the number of plus-strand mutations by no more than half. There
are also other mechanisms which may make significant contributions to
the A-rich nature of the HIV-1 genome. For example, it has been
suggested that imbalances in the dNTP pools leads to G
A
hypermutations (25); this could also contribute to an A-rich genome.
If the bias for substituting A's for other bases also occurs when RT copies the RNA genome, it would give rise to a T-rich genome. The error rate for HIV-1 RT copying an RNA polymerase generated RNA template has been measured (7, 8, 14, 15). However, the overall frequency measured in such experiments is a combination of two error rates: the error rate of the RT using the RNA template and the error rate of the DNA-dependent RNA polymerase used to generate the RNA template. Until the error rate of DNA-dependent RNA polymerases can be accurately measured, it will not be easy to determine how accurately RT copies an RNA template compared with a DNA template.
Comparing the results that we obtained with wild-type HIV-1 RT and the two mutants, Y115F and Y115V, the most striking differences are not in the rate of mutation but in the spectrum of mutations that were obtained and in the hot spots. Y115F is perhaps 1.5- to 2-fold less error prone than wild-type HIV-1 RT, and Y115V is 3- to 4-fold less error prone than wild-type HIV-1 RT; however, the major differences are in the nature of the mutations that were obtained. Both Y115F and Y115V make fewer frameshift errors than does the wild-type enzyme; both mutant enzymes seem less prone to make errors that involve a misalignment/slippage mechanism. Both make about as many transition errors as the wild-type enzyme but are less prone to make transversion errors.
We were especially interested in the fidelity of Y115V. Both the Y115V mutant of HIV-1 RT and the corresponding F155V mutant of murine leukemia virus (MLV) RT can incorporate UTP into DNA much more efficiently than the corresponding wild-type enzymes (9, 12). This raises a question: does this ability to incorporate ribonucleotides reflect a specific or a general change in enzyme specificity? Furthermore, does this change in the ability of the enzyme(s) to distinguish dNTPs and NTPs extend to an inability of the enzyme(s) to properly distinguish the individual dNTPs? It has been argued that the change in the F155V mutant of MLV RT specifically alters a "gate" that blocks the incorporation of ribonucleotides, which would not necessarily imply a loss of fidelity. However, there is a complex array of changes in the enzymatic properties of Y115V that are not all easily explained by a simple gate model (9). Moreover, some of the properties of the Y115V mutant of HIV-1 RT and the F155V mutant of MLV RT appear to be different (9, 12).
Previous reports on the fidelity of Y115 mutants were based either on a biochemical measure of misinsertion (Y115F) (18) or on mispair extension (Y115F and Y115V) (19). Both Y115F and Y115V were reported to be more error prone than the wild-type enzyme; in the mispair extension assay, Y115V had a lower fidelity than Y115F (19). Although mispair extension is a component of fidelity, it does not provide a measure of misincorporation but only a measure of the ability to extend a mispaired end. Moreover, recent reports have shown that HIV-1 RT can remove the 3' terminus of a primer. This process involves the reversal of the normal polymerization reaction and can proceed with either pyrophosphate or an NTP acting as a pyrophosphate donor (2, 20). It is possible that this reaction can also proceed with a dNTP as a pyrophosphate donor, and the mispair extension assays may, in some cases, be affected by the ability of RT (either wild type or mutant) to carry out this unblocking reaction and then extend the primer. However, the concentrations of NTPs necessary for this reaction to be efficient are relatively high (millimolar), so the contribution of this mechanism to the standard mispair extension assays may be small.
Both the published data on the fidelity of Y115F and Y115V and our data suggest that the overall change in fidelity is relatively small. However, our data also show, despite a modest change in fidelity, that these two amino acid substitutions have a much more dramatic effect on the type(s) of errors. In this way, the effects of the Y115V mutant on fidelity are somewhat similar to the effects on fidelity of mutating another amino acid that is part of the dNTP-binding site of HIV-1 RT, M184. Substitution of the methionine at position 184 with I or V has a relatively modest effect on the overall error rate (~4-fold) but a much greater effect on the spectrum of mutations that are obtained (11). Another mutation at the dNTP-binding site, Q151, has a modest effect on the spectrum of mutations (21). Taken together, these results suggest that making modest changes in the amino acids that form the dNTP-binding site affects both the types of errors and the precise sequences that are mutational hot spots to a much greater extent than the overall fidelity.
| |
ACKNOWLEDGMENTS |
|---|
We thank Hilda Marusiodis for typing the manuscript, Marilyn Powers for help with the sequencing, and Anne Arthur for expert editorial assistance. We also thank Pat Clark and Peter Frank for purifying wild-type and mutant HIV-1 RT.
This research was sponsored by the National Cancer Institute, DHHS, under contract with ABL, and by NIGMS.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: HIV Drug Resistance Program, National Cancer Institute-FCRDC, P.O. Box B, Building 539, Room 130A, Frederick, MD 21702-1201. Phone: (301) 846-1619. Fax: (301) 846-6966. E-mail: hughes{at}ncifcrf.gov.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Abbots, J.,
K. Bebenek, and T. A. Kunkel.
1993.
Mechanism of HIV-1 reverse transcriptase. Termination of processive synthesis on a natural DNA template is influenced by the sequence of the template-primer stem.
J. Biol. Chem.
268:10312-10323 |
| 2. | Arion, D., N. Kaushik, S. McCormick, G. Borkow, and M. A. Parniak. 1998. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37:15908-15917[CrossRef][Medline]. |
| 3. |
Bebenek, K.,
J. Abbotts,
J. D. Roberts,
S. H. Wilson, and T. A. Kunkel.
1989.
Specificity and mechanism of error-prone replication by human immunodeficiency virus-1 reverse transcriptase.
J. Biol. Chem.
264:16948-16956 |
| 4. |
Bebenek, K.,
J. Abbotts,
S. H. Wilson, and T. A. Kunkel.
1993.
Error-prone polymerization by HIV-1 reverse transcriptase. Contribution of template-primer misalignment, miscoding, and termination probability to mutational hot spots.
J. Biol. Chem.
268:10324-10334 |
| 5. |
Bebenek, K.,
W. A. Beard,
J. R. Casas-Finet,
H.-R. Kim,
T. A. Darden,
S. H. Wilson, and T. A. Kunkel.
1995.
Reduced frameshift fidelity and processivity of HIV-1 reverse transcriptase mutants containing alanine substitutions in helix H of the thumb subdomain.
J. Biol. Chem.
270:19516-19523 |
| 6. | Bebenek, K., and T. A. Kunkel. 1991. Analyzing fidelity of DNA polymerases. Methods Enzymol. 262:217-232. |
| 7. | Boyer, J. C., K. Bebenek, and T. A. Kunkel. 1996. Analyzing the fidelity of reverse transcription and transcription. Methods Enzymol. 275:523-537[Medline]. |
| 8. |
Boyer, J. C.,
K. Bebenek, and T. A. Kunkel.
1992.
Unequal human immunodeficiency virus type 1 reverse transcriptase error rates with RNA and DNA templates.
Proc. Natl. Acad. Sci. USA
89:6919-6923 |
| 9. |
Boyer, P. L.,
S. G. Sarafianos,
E. Arnold, and S. H. Hughes.
2000.
Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase.
Proc. Natl. Acad. Sci. USA
97:3056-3061 |
| 10. | Ding, J., K. Das, Y. Hsiou, S. G. Sarafianos, A. D. Clark, Jr., A. Jacobo-Molina, C. Tantillo, S. H. Hughes, and E. Arnold. 1998. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 Å resolution. J. Mol. Biol. 284:1095-1111[CrossRef][Medline]. |
| 11. |
Drosopoulos, W. C., and V. R. Prasad.
1998.
Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro.
J. Virol.
72:4224-4230 |
| 12. |
Gao, G.,
M. Orlova,
M. M. Georgiadis,
W. A. Hendrickson, and S. P. Goff.
1997.
Conferring RNA polymerase activity to a DNA polymerase: a single residue in reverse transcriptase controls substrate selection.
Proc. Natl. Acad. Sci. USA
94:407-411 |
| 13. |
Huang, H.,
R. Chopra,
G. L. Verdine, and S. C. Harrison.
1998.
Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.
Science
282:1669-1675 |
| 14. | Hubner, A., M. Kruhoffer, F. Grosse, and G. Krauss. 1992. Fidelity of human immunodeficiency virus type 1 reverse transcriptase in copying natural RNA. J. Mol. Biol. 223:595-600[CrossRef][Medline]. |
| 15. | Ji, J., and L. A. Loeb. 1992. Fidelity of HIV-1 reverse transcriptase copying RNA in vitro. Biochemistry 31:954-958[CrossRef][Medline]. |
| 16. | Kunkel, T. A. 1990. Misalignment-mediated DNA synthesis errors. Biochemistry 29:8003-8011[CrossRef][Medline]. |
| 17. |
Kunkel, T. A., and A. Soni.
1988.
Mutagenesis by transient misalignment.
J. Biol. Chem.
263:14784-14789 |
| 18. | Martin-Hernandez, A. M., E. Domingo, and L. Menendez-Arias. 1996. Human immunodeficiency virus type 1 reverse transcriptase: role of Tyr115 in deoxynucleotide binding and misinsertion fidelity of DNA synthesis. EMBO J. 15:4434-4442[Medline]. |
| 19. |
Martin-Hernandez, A. M.,
M. Gutierrez-Rivas,
E. Domingo, and L. Menendez-Arias.
1997.
Mispair extension fidelity of human immunodeficiency virus type 1 reverse transcriptases with amino acid substitutions affecting Tyr115.
Nucleic Acids Res.
25:1383-1389 |
| 20. |
Meyer, P. R.,
S. E. Matsuura,
A. G. So, and W. A. Scott.
1998.
Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism.
Proc. Natl. Acad. Sci. USA
95:13471-13476 |
| 21. |
Rezende, L. F.,
K. Curr,
T. Ueno,
H. Mitsuya, and V. R. Prasad.
1998.
The impact of multidideoxynucleoside resistance-conferring mutations in human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and error specificity.
J. Virol.
72:2890-2895 |
| 22. |
Roberts, J. D.,
K. Bebenek, and T. A. Kunkel.
1988.
The accuracy of reverse transcriptase from HIV-1.
Science
242:1171-1173 |
| 23. | Telesnitsky, A., and S. P. Goff. 1997. Reverse transcription and the generation of retroviral DNA, p. 121-160. In J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 24. | Tisdale, M., T. Alnadaf, and D. Cousens. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Chemother. 41:1094-1098[Abstract]. |
| 25. | Vartanian, J.-P., U. Plikat, M. Henry, R. Mahieux, L. Guillemot, A. Meyerhans, and S. Wain-Hobson. 1997. HIV genetic variation is directed and restricted by DNA precursor availability. J. Mol. Biol. 270:139-151[CrossRef][Medline]. |
| 26. | Wainberg, M. A., W. C. Drosopoulos, H. Salomon, M. Hsu, G. Borkow, M. Prniak, Z. Gu, Q. Song, J. Manne, S. Islam, G. Castriota, and V. R. Prasad. 1996. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271:1282-1285[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»